News tagged with novo nordisk

Related topics: diabetes · type 2 diabetes

Tretten approved for genetic clotting disorder

(HealthDay)—Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.

Dec 23, 2013
popularity0 comments 0

Subscribe to rss feed